← Jürgen C. Becker

Papers by Jürgen C. Becker

Page 1 · newest first

1. Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC-TRIM registryBritish Journal of Dermatology · 2026
2. Genomic landscape of sweat gland carcinomas: Clinical applications and future directionsEuropean Journal of Cancer · 2026
3. Different Hyaluronic Acid‐Based Formulations Exert Composition‐Dependent Effects on Human Fibroblasts and OsteoblastsJournal of Periodontal Research · 2026
4. Pharmacologic reversion of Merkel cell carcinoma via CBP/p300 inhibitionProceedings of the National Academy of Sciences · 2025
5. High-resolution spatial transcriptomics uncover epidermal-dermal divergences in Merkel cell carcinoma: spatial context reshapes the gene expression landscapeOncogene · 2025
6. Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy responseJournal for ImmunoTherapy of Cancer · 2025
7. IFN γ and the IFN γ Signaling Pathways in Merkel Cell CarcinomaCancers · 2025
8. Leukemia cutis with concomitant acrodermatitis chronica atrophicans and chronic B‐cell lymphocytic leukemia: complete clearance under doxycycline therapyJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2025
9. Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patientsEuropean Journal of Cancer · 2025
10. Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREGEuropean Journal of Cancer · 2025
11. Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trialBritish Journal of Dermatology · 2025
12. Inhibitory Immune Checkpoints beyond Programmed Cell Death Ligand 1 in Merkel Cell Carcinoma: Abundant Expression of TIGIT Independent of the Presence of Merkel Cell Polyoma VirusActa Dermato Venereologica · 2025
13. Impaired Overall Survival of Melanoma Patients Due to Antibiotic Use Prior to Immune Checkpoint Inhibitor Therapy: Systematic Review and Meta-AnalysisCancers · 2025
14. German‐Austrian guideline on screening for anal dysplasia and anal carcinoma in people living with HIVJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2025
15. Kit-mediated autophagy suppression driven by a viral oncoprotein emerges as a crucial survival mechanism in Merkel cell carcinomaAutophagy · 2025
16. The significance of PAX5 in Merkel cell carcinomaThe Journal of Pathology · 2025
17. Preclinical in vitro and in vivo evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomasBritish Journal of Dermatology · 2025
18. Low Intratumoral CD200 Protein Expression in Primary Merkel Cell Carcinoma Is a Strong Predictor for Disease RelapseCancers · 2025
19. Immune checkpoint inhibitors for children with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma: A case presentation and brief reviewJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2025
20. Crosstalk between CLL and cutaneous T-cell lymphoma: MIF-CD74 axis and dysregulated inflammatory signalingEJC Skin Cancer · 2025
21. Tunlametinib for NRAS-mutated pediatric melanoma arising from a giant congenital melanocytic nevus: A rapidly progressive caseEJC Skin Cancer · 2025
22. The Effect of NiTi Brush, Polishing Brush, and Chemical Agent on the Dental Implant Surface Morphology and CytocompatibilityClinical Implant Dentistry and Related Research · 2024
23. Intratumoural programmed cell death protein expression in 92 patients with atypical fibroxanthoma and pleomorphic dermal sarcomaJournal of the European Academy of Dermatology and Venereology · 2024
24. Short- and long-term immunosuppressive effects of melanoma influence the prognostic value of the sentinel lymph node statusEuropean Journal of Cancer · 2024
25. Early versus late response to PD-1-based immunotherapy in metastatic melanomaEuropean Journal of Cancer · 2024
26. Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signatureFrontiers in Oncology · 2024
27. Analyses of combined Merkel cell carcinomas with neuroblastic components suggests that loss of T antigen expression in Merkel cell carcinoma may result in cell cycle arrest and neuroblastic transdifferentiationThe Journal of Pathology · 2024
28. Introducing MCC-PS: a novel prognostic score for Merkel cell carcinomaFrontiers in Oncology · 2024
29. Cellular Dynamics Upon Immune Checkpoint Inhibition2024
30. Merkel cell polyomavirus pan‐T antigen knockdown reduces cancer cell stemness and promotes neural differentiation independent of RB1Journal of Medical Virology · 2024
31. Incidence and Relative Survival of Patients with Merkel Cell Carcinoma in North Rhine-Westphalia, Germany, 2008–2021Cancers · 2024
32. Porocarcinomas with PAK1/2/3 fusions: a series of 12 casesHistopathology · 2024
33. A Prospective Study Investigating Immune Checkpoint Molecule and CD39 Expression on Peripheral Blood Cells for the Prognostication of COVID-19 Severity and MortalityViruses · 2024
34. Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and UpdateVaccines · 2024
35. S1‐Leitlinie TalgdrüsenkarzinomJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2024
36. Merkel-cell carcinoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-upESMO Open · 2024
37. S1‐Guideline Sebaceous CarcinomaJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2024
38. High intratumoral 5-hydroxymethylcytosine levels protect against disease relapse in patients with atypical fibroxanthoma and pleomorphic dermal sarcomaBritish Journal of Dermatology · 2024
39. Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic UpdatesAmerican Journal of Clinical Dermatology · 2024
40. The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrationsEuropean Journal of Cancer · 2024
41. Comparative efficacy of combined CTLA-4 and PD-1 blockade vs. PD-1 monotherapy in metastatic melanoma: a real-world studyBJC Reports · 2024
42. T antigen–specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinomaJournal of Clinical Investigation · 2024
43. Eligibility and efficacy of a CPC‐ and CHX ‐based antiviral mouthwash for the elimination of SARS‐CoV ‐2 from the saliva: A randomized, double‐blind, controlled clinical trialJournal Of Clinical Periodontology · 2023
44. S3 guideline „actinic keratosis and cutaneous squamous cell carcinoma“ – update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and preventionJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2023
45. Prognostic Performance of Inflammatory Biomarkers Based on Complete Blood Counts in COVID-19 PatientsViruses · 2023
46. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIMEBioMedicine · 2023
47. Prognostic factors in the primary care of patients with Merkel cell carcinoma: A monocentric cohort study of 108 patients from a tertiary referral centreJEADV Clinical Practice · 2023
48. The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary resultsJournal of Cancer Research and Clinical Oncology · 2023
49. Reduced Staphylococcus Abundance Characterizes the Lesional Microbiome of Actinic Keratosis Patients after Field-Directed TherapiesMicrobiology Spectrum · 2023
50. Mesenchymal–epithelial transition in lymph node metastases of oral squamous cell carcinoma is accompanied by ZEB1 expressionJournal of Translational Medicine · 2023